Acta Pharmaceutica Sinica B2024cited by 90position: middledoi
ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2022cited by 57position: middledoi